

Efficacy of ginseng supplements on disease-related fatigue A systematic review and meta-analysis

Jianxun Zhu, MM^a, Xiaoru Xu, MD^a, Xin Zhang, MD^a, Yue Zhuo, MD^a, Shaotao Chen, MM^a, Chongwen Zhong, MD^a, Mingjun Liu, MM^{a,*}, Zhihong Wang, MM^{a,*}

Abstract

Background: Ginseng has been believed to provide energy, physical health, and well-being to patients for hundreds of years. Fatigue is a multidimensional symptom with unknown etiology and varying severity, and lots of patients suffer from fatigue.

Methods: We search for research of ginseng treatment of disease-related fatigue in adult patients in Pubmed, Embase, Medline, and Cochrane library. Two independent reviewers assessed included studies and met to develop consensus on included studies. And we used Review Manager 5.3 software to evaluate the risk of bias.

Results: The present meta-analysis included 12 randomized controlled trial containing 1298 patients. In the fixed-effect metaanalysis of 12 randomized controlled trial, ginseng supplements had a statistically significant efficacy on disease-related fatigue reduction (standardized mean difference = 0.33, 95% confidence interval = 0.44–0.22).

Conclusions: The use of ginseng supplements is benefit for patients to reduce disease-related fatigue.

Abbreviations: BFI = Brief Fatigue Inventory, CFSQ = Chalder Fatigue Severity Questionnaire, CI = confidence interval, FACIT-F = Functional Assessment Of Chronic Illness Therapy-Fatigue, FSS = Fatigue Severity Scale, KFSS = Krupp Fatigue Severity Scale, MFIS = Modified Fatigue Impact Scale, MFSI-SF = Multidimensional Fatigue Symptom Inventory-Short Form, NRS = numerical rating scale, QOL = quality of life, RCT = randomized controlled trial, RDFS = Real-Time Digital Fatigue Score, SMD = standardized mean difference, VAS = visual analog scale.

Keywords: disease-related, fatigue, ginseng supplements, meta-analysis

1. Introduction

Fatigue is a physiological phenomenon that often occurs in the human body. Human with fatigue are characterized by low mood, low vitality, boredom, and reduced sleep; severe fatigued people will also have muscle pain, muscle weakness, and weight loss.^[1,2] Disease-related fatigue, a type of fatigue, is a main feeling of fatigue caused by the disease itself or its treatment, and cancer-related fatigue is the most common.^[3,4] Disease-related fatigue is an accompanying symptom and also seriously affects the patient's compliance with treatment.^[5,6] For fatigue reduction, most patients are given alternative and complementary, including scientific sports training, nutritional supplements, Chinese medicine supplements, etc.^[7,8]

Ginseng, a kind of medicine or health food widely used to treat fatigue in the world, has 2 major subgroup, Korean ginseng and American ginseng. Ginseng is the dried root of the Araliaceae plant ginseng, a traditional nourishing and health-preserving precious medicinal material in China,

The authors have no conflicts of interest to disclose.

which has the functions of invigorating vitality, rejuvenating the pulse, replenishing the spleen and lungs, nourishing body fluid, nourishing blood, and soothing mind.^[9,10] According to the published survey report, Korean ginseng and its extract are being accepted by consumers in Western countries for strengthening immunity and reducing fatigue.^[11] Because of the wild use of ginseng, more and more scholars are paying attention to the efficacy of ginseng as a treatment drug and the effect of eliminating fatigue as a nutritional supplement. To date, about 40 kinds of active substances from ginseng have been found to have a variety of biological activities, such as antioxidative stress, immune regulation, antitumor activity, antiradiation, antiaging, etc.^[12,13] However, these effects of ginsengs lack sufficient clinical research support.

Recently, some randomized controlled trials (RCTs) about the efficacy of ginseng supplements on disease-related fatigue have been published, but the conclusion is still unclear. And the topic of the efficacy of ginseng supplements on disease-related fatigue is still

How to cite this article: Zhu J, Xu X, Zhang X, Zhuo Y, Chen S, Zhong C, Liu M, Wang Z. Efficacy of ginseng supplements on disease-related fatigue: A systematic review and meta-analysis. Medicine 2022;101:26(e29767).

Received: 1 November 2021 / Received in final form: 21 February 2022 / Accepted: 23 May 2022

http://dx.doi.org/10.1097/MD.000000000029767

JZ and XX contributed equally to this study.

All data generated or analyzed during this study are included in this published article [and its supplementary information files].

^a Changchun University of Chinese Medicine, Jingyue Economic Development District, Changchun, People's Republic of China.

^{*}Correspondence: Mingjun Liu, Changchun University of Chinese Medicine, No. 1035, Boshuo Rd, Jingyue Economic Development District, Changchun 130117, People Republic of China (e-mail: liumj0592@126.com).

^{*}Correspondence: Zhihong Wang, Changchun University of Chinese Medicine, Jingyue Economic Development District, Changchun 130117, People Republic of China (e-mail: wzh6172555@163.com).

Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. 2022This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.




Figure 1. Flow diagram for identification of relevant clinical trials.

very few. In the present study, we investigated the efficacy of ginseng supplements on disease-related fatigue using a meta-analysis.

2. Methods

2.1. Ethics statement

As a study of systematic review and meta-analysis, the present study did not recruit any volunteers and did not conduct any

human or animal experiments, so this study does not require ethical approval.

2.2. Search strategy

In January 2021, we searched for studies related to the effect of ginseng supplements on disease-related fatigue. The language is limited to English, and time is from January 2010 to December 2020. Two

ble

General characteristics of studies in the final analysis (n = 12).

Study (author, year)	Randomization	Description of randomization methods	Double blind	Using identical placebo	Follow-up reporting	Total score
Barton et al, 2010 ^[15]	1	1	1	1	1	5
Kim et al, 2011 ^[16]	1	1	1	1	1	5
Barton et al. 2013 ^[17]	1	1	1	1	1	5
Kim et al, 2013 ^[18]	1	1	1	0	1	4
Etemadifar et al, 2013 ^[19]	1	1	1	1	1	5
Braz et al, 2013 ^[20]	1	1	1	1	1	5
Hong et al, 2016 ²¹	1	1	1	1	1	5
Hee et al, 2017 ^[22]	1	1	1	1	1	5
Pourmohamadi et al, 2017 ^[23]	1	1	1	1	1	5
Yennurajalingam et al, 2018[24]	1	1	1	1	1	5
Sung et al, 201925	1	1	1	1	0	4
Kim et al, 2020 ²⁶	1	1	1	1	1	5

reviewers independently selected trials and extracted data according to predetermined selection criteria. Any inconsistencies will eventually be resolved through mutual discussion. Key words for literature search are as follow: "American Ginseng", "Asian Ginseng", "Panax ginseng", "Korean ginseng", "Korean red ginseng", "Panax ginseng", "fatigue", "weariness", "tiredness", "exhaustion".

2.3. Selection criteria

Studies included in the present meta-analysis are related to the effect of ginseng supplements on disease-related fatigue, so the studies meet the following criteria: participants with underlying diseases, RCT, any type of ginseng supplement as an intervention, placebo as a control intervention, and fatigue evaluation plan is clear.

2.4. Data extraction

Two reviewers independently extracted the following key data by reading the full text: author, publication date, methods of randomization, description of randomization, methods of blind, participant characteristics (gender, disease, and region), sample size, ginseng category, intervention plan, fatigue evaluation program, and outcome of fatigue evaluation.

2.5. Statistical analysis and heterogeneity

Review Manager 5.3 software was used for meta-analysis. We investigated the difference in fatigue reduction between placebo intervention group and ginseng supplement intervention group in patients. Due to the different scales for fatigue reduction across the studies, we used standardized mean difference (SMD) as a main effect size to calculate those differences. Each effect size is given its point estimate and 95% confidence interval (CI). If there is no statistical heterogeneity (P > .1), use fixed-effects model analysis. If there is heterogeneity (P < .1), analyze the source of heterogeneity first. If there is no obvious clinical heterogeneity and no definite source of statistical heterogeneity can be found, random-effects model analysis can be used; if there is obvious clinical heterogeneity or methodological heterogeneity or incomplete data provided, then perform descriptive analysis. If there is significant statistical heterogeneity due to the different methodological quality of the included studies, low-quality studies can be removed for sensitivity analysis.

3. Results

3.1. Selection of trials

There were 310 studies found after searching in 4 databases (Fig. 1). After removing duplicate literature, 238 studies were

included. Next, 2 reviewers selected 27 studies after reading the title and abstract of these trials. At last, we included 12 studies in final analysis after reading full text of 27 studies, and excluded 13 studies because of selection criteria.

3.2. Trials quality evaluation

Jadad scale was used to assess the methodological quality of these studies in the present meta-analysis from 5 dimensions,^[14] including randomization, description of randomization methods, double-blind, using identical placebo, and follow-up reporting. As shown in Table 1, all included studies were scored 3 to 5, so the study included in the present meta-analysis was low risk of bias. In addition, Review Manager 5.3 software was also used for trials' quality: the risk of bias graph (Fig. 2) and risk of bias summary (Fig. 3).

3.3. Characteristics s of included trails

General characteristics of studies (n = 12) in the final analysis are shown in Table 2. A total of 1298 participants were included in final trials, and the dose of ginseng supplement intervention ranged from 100 to 3000 mg/d, and the duration from 3 to 16 weeks. The area where the trials were located included United States (n = 4), South Korea (n = 5), Iran (n=2), and Brazil (n = 1). The type of ginseng included American ginseng (n = 5) and Asian ginseng (n = 7). The tools for evaluating fatigue are so many, including Brief Fatigue Inventory (BFI), Fatigue Severity Scale, Real-Time Digital Fatigue Score (RDFS), Modified Fatigue Impact Scale, Multidimensional Fatigue Symptom Inventory-Short Form(MFSI-SF), numerical rating scale, visual analog scale, Multiple Sclerosis Quality of Life Questionnaire-54, Krupp Fatigue Severity Scale; quality of life, Functional Assessment of Chronic Illness Therapy-Fatigue, and Chalder Fatigue Severity Questionnaire.

3.4. Efficacy of ginseng supplements on disease-related fatigue reduction

We investigated the efficacy of ginseng supplements on disease-related fatigue reduction, but some included trials were descriptive for the results of fatigue assessment, such as Pourmohamadi et al ^[23] and Sung et al^[25]; so we excluded these 2 trials in meta-analysis. In addition, ginseng interventions in some trials have multiple subgroups, and we only included the data in highest dose of ginseng supplement, such as Barton et al,^[15] Kim et al,^[16] and Kim et al,^[18] As shown in Figure 4, the funnel chart analysis of 10 studies showed the left-right symmetry, which indicated that there is no publication bias. As shown in Figure 5, there is no statistical heterogeneity among the 10 studies (I² = 35%, P = .13). Analysis using a fixed-quantity effect model showed that there




Figure 2. Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies.




Figure 3. Risk of bias summary: review authors' judgments about each risk of bias item for each included study.

were statistical differences between the experimental group and the control group (SMD = -0.33, 95% CI = -0.44 to -0.22).

4. Discussion

In recent years, domestic and foreign scholars have conducted pharmacological studies, clinical observations, and epidemiological investigations on the effective ingredients of ginseng, and the results have confirmed that ginseng has improved microcirculation, improved tissue antihypoxia ability, and inhibited platelet aggregation, antitumor, and antiaging, antiradiation, antifatigue, and other biological activities.^[27, 28] In fatigue, previous studies have found that ginseng can improve thinking and physical activity.^[29, 30] However, large samples of clinical research data are insufficient.

	Parti	Participants (n)				Tre	Treatment		Fatique	
Study (author, year)	Control	Intervention	Design	Duration	Disease	Control	Intervention (ginseng)	Type of ginseng	evaluation tools	Outcome
Barton et al, 2010 ^[15]	Female: 45 Male: 24	Female: 141 Male: 72	RCT	8 wk	Cancer	Placebo	750, 1000, or 2000 mg/d	Wisconsin ginseng	BFI, SF-36	BFI (AUC): 460 (placebo), 467 (750 mg/d), 480 (1000 mg/d), and 551 (2000 mg/d), $P = .08$; SF-36: 7.3 (placebo), 7.8 (750 mg/d), 10.5 (1000 mg/d), and 14.6 (2000 mg/d), SF-36: 7.3 (placebo), 7.8 (750 mg/d), 10.5 (1000 mg/d), and 14.6 (2000 mg/d), 10.5 (1000 mg/d), 10.5 (10000 mg/d), 10.5 (1000 mg/d
Kim et al 2011 ^[16]	Female: 44 Male: 3		RCT	6 wk	Multiple sclerosis	Placebo	100, 200, 400 mg/d	American ginseng	FSS, RDFS, MFIS	r = .00. FSS: baseline (5.7 ± 0.98), placebo (5.5 ± 1.3), ginseng (5.5 ± 1.3), $P = .48$; MFIS: baseline (47.0 ± 15.0), placebo (43.7 ± 16.7), ginseng (42.7 ± 15.7), $P = .23$; RDFS: baseline (4.4 ± 1.6), placebo (4.2 ± 1.8), ginseng (4.2 ± 1.6), $P = .08$; RDFS with mixed modeling: baseline (4.2 ± 0.3), placebo (4.1 ± 0.3), ginseng
Barton	Female: 138	Female: 128	RCT	8 wk	Cancer	Placebo	2000 mg/d	Wisconsin	MFSI-SF	(3.9 ± 0.3) , $P = .0031$. Change score of MFSI-SF vs baseline: placebo (10.3), ginseng (20), $P = .003$.
et al, 2013 ^{uu} Kim	Male: 33 Female: 24	Male: 42 Female: 45	RCT	4 wk	Idiopathic chronic	Placebo	1000 or	ginseng Panax ginseng	NRS, VAS	NRS: placebo (18.8 \pm 2.9), 1 g of ginseng (15.1 \pm 6.5), 2g of ginseng (13.8 \pm 6.2),
et al, 2013 ^[18] Etemadifar	Male: 6 Female: 26	Male: 15 Female: 26	RCT	3 mo	fatigue multiple sclerosis	Placebo	2000 mg/d 250 mg/d	C.A. Meyer Korean ginseng	MFIS	P < .01; VAS: placebo (5.8 ± 1.3), 2g of ginseng (4.4 ± 1.8), $P < .01$. Placebo: baseline (22.23 ± 13.21), after intervention (23.69 ± 12.94), $P = .68$;
et al, 2013 ^{na} Rraz	Male: U Female: 13	Male: U Female: 13	RCT	10 WK	Fihromvalcia	Placeho	100 ma/d	Panax ninsend	VAS	ginseng: baseline (31.69 \pm 14.9), atter intervention (23.65 \pm 12.8), P = .042. Statistically significant difference in the change of fatigue scores between 2 groups (P = 0.46). VAS fations on statistically significant differences in innovement hetween the
et al 2013 ^[20]	Male: 0	Male: 0	LCO		vittet oilodooloool					mean scores of the 3 groups ($F(2) = 0.9$; $P > 0.5$). Discrete hording ($70.0 + 1.4$), the remember of $1.2 = 0.9$; $P > 0.5$
et al, 2016 ²¹	Male: 50		2		INVITATION INTO TALLY			ginseng	2	process: baseline (c2.52 ± 17.1), and must version (c2.52 ± 12.5), $T = .227$, ginseng: baseline (33.0 ± 11.6), after intervention (24.3 ± 8.4), $P < .001$. No statistically significant difference in the change of fatigue scores between 2 mons $(D = .273)$
Hee	Female: 15	Female: 15	RCT	12 wk	Epithelial ovarian	Placebo	3000 mg/d	Red ginseng	BFI	groups (r = .22.1). Placebo: baseline (19.55±10.33), after intervention (11.38±11.84), P = .084;
et al, 2017 ^[23] Pourmohamadi et al, 2017 ^[23]	Male: 0 Female: 29 Male: 31	Male: 0 Female: 26 Male: 28	RCT	30 d	cancer Nonmetastatic cancer	Placebo	100 mg/d	Panax ginseng	BEK test	guiserig, baseline ($z_{2,2}4 \pm 1/29$), and intervention ($1.4.23 \pm 1/29$), $r =14$ Placebo: baseline (good [13], depression [34] and severe [13]), after intervention (good [11], depression [39] and severe [10]), $P = .887$;
:						·				ginseng: baseline (good [13], depression [30] and severe [9]), after intervention (good [44], depression [10] and severe [0]), $P < .0001$.
Yennurajalingam et al, 2018 ^{/24}	Female: 24 Male: 40	Female: 29 Male: 34		4 WK	Advanced cancer	Placebo	400 mg twice/d	Panax ginseng C.A. Meyer	FAGIL-F	The mean (SU) FAC(1-F subscale scores at baseline, day 15, and day 29 were 22.4 (10.1), 29.9 (10.6), and 30.1 (11.6) for ginseng ($P < .001$), and 24.0 (9.4), 30.0 (10.1), and 30.4 (11.5) for placebo ($P < .001$). Mean (SD) improvement in the FACIT-F subscale at day 29 was not significantly different in the PG than in the placeho or ror or $(7.5 (12.7) \times 6.5 (9.9) \cdot P = 6.7)$
Sung et al, 2019 ²⁵	Female: 18 Male: 5	Female: 15 Male: 9	RCT	10 wk	Moderated chronic fatigue	Placebo	3000 mg/d	Korean red ginseng	VAS, FSS, CFSQ	Each group had sign address process group way for the Fargue VAS, FSS and CFSQ from baseline (week 0, visit 2) to 6 or 10 wk, but no statistically significant difference in the channe of farine scores between 2 mons.
Kim et al, 2020 ^[26]	Female: 80 Male: 123	Female: 82 Male: 124	RCT	16 wk	Colorectal cancer	Placebo	500 mg twice/d	Korean red ginseng	BFI	For the mean AUC change from baseline of BFI over 16 with the full analysis set, the ginseng group showed a benefit compared to the placebo group for all questions.

Table 2

5




Figure 4. Funnel plot for the effect of ginseng supplements on the disease-related fatigue. SE = standard error, SMD = standardized mean difference.

In this meta-analysis of RCTs, we aim to investigate the efficacy of ginseng supplements on disease-related fatigue reduction based on 12 RCTs, and we found that ginseng supplements had a statistically significant efficacy on disease-related fatigue reduction (SMD = 0.33, 95% CI = 0.44-0.22) based on Cohen rule of thumb.^[31] However, it should be noted that although 12 RCTs were included in final analysis, 2 studies (Pourmohamadi et al^[23] and Sung et al^[25]) were excluded in final meta-analysis in Review Manager 5.3 software, because the evaluation of fatigue in these 2 studies is count data. In addition, ginseng interventions in some trials have multiple subgroups, and we only included the data in highest dose of ginseng supplement, such as Barton et al,^[15] Kim et al,^[16] and Kim et al.^[18] Taken together, the results of our meta-analysis that high dose of ginseng supplements had a statistically significant efficacy on disease-related fatigue reduction.

The antifatigue effect of ginseng is time and dose dependent. Barton et al^[15] found that the area under the curve analysis of activity interference from BFI was 460, 467, 480, and 551 in the placebo group, 750 mg/d group, 1000 mg/d group, and 2000 mg/d group, respectively. Similarly, change from baseline in the vitality subscale of the Short Form 36 (SF-36) was 7.3, 7.8, 10.5, and 14.6, respectively. Moreover, the results of low-dose ginseng supplement intervention experiments also showed that it is ineffective against fatigue, such as in Kim et al,^[16] Braz et al,^[20] and Yennurajalingam et al.^[24] However, the type of ginseng was also important. The low dose of Asian ginseng (250 mg/d in Etemadifar et al^[19] and 100 mg/d in Pourmohamadi et al^[23]) significantly reduced fatigue in patients, which was compared with placebo group.

Lots of possible biological mechanisms for the efficacy of ginseng supplements on fatigue have been announced. The feeling of fatigue is thought to be related to excessive consumption of muscle sugar and blood sugar, that is, when muscle glycogen and blood sugar uptake speed is greater than the speed of liver glycogen decomposition into the blood, it will cause a




Figure 5. Forrest plot for the effect of ginseng supplements on the disease-related fatigue.

decrease in blood sugar, a decline in work ability, and induce fatigue.^[32,33] Fortunately, Yokozawa et al^[34] found that the content of hepatic glucose-6-phosphate dehydrogenase activity increased rapidly 2 to 4 hours after administration of ginseng extract. Furthermore, reducing lactic acid accumulation is another important biological mechanism of ginseng to fight fatigue. The increase of lactic acid in the human body leads to an increase in the concentration of hydrogen ions, which interferes with the physiological activity of calcium ions, affects the coupling process of muscle excitation/contraction, reduces muscle contraction strength, and induces fatigue.^[35,36] Previous studies have found that ginseng intervention can increase lactic acid metabolism by increasing oxygen intake and lactate dehydrogenase activity in mice.^[37]

In our meta-analysis, our results are consistent with animal and in vitro studies. However, our meta-analysis has limitations: only 1298 participant, the sample size is small, and some studies are partially added. Nonetheless, ginseng is beneficial in reducing disease-related fatigue based on our study.

Author contributions

Mingjun Liua and Zhihong Wang designed and funded this study; Jianxun Zhua and Xiaoru Xua completed the writing and data analysis of this study; Jianxun Zhua, Xiaoru Xua, Xin Zhanga, Yue Zhuoa, Shaotao Chena, and Chongwen Zhonga assisted in literature review, data extraction and analysis.

Reference

- Sulheim D, Fagermoen E, Sivertsen YS, et al. Cognitive dysfunction in adolescents with chronic fatigue: a cross-sectional study. Arch Dis Child. 2015;100:838–44.
- [2] Ganiats TG. Redefining the chronic fatigue syndrome. Ann Intern Med. 2015;162:653–4.
- [3] Capogrosso RF, Cozzoli A, Sblendorio V, et al. P4.26 Toward the identification of druggable pathways involved in disease-related fatigue in Duchenne muscular dystrophy: in vivo and ex vivo studies in dystrophic mdx mice. Neuromuscul Disord. 2011;21:712–712.
- [4] Weert EV. Cancer-related fatigue: predictors and effects of rehabilitation. Oncologist. 2006;11:184–96.
- [5] Fernández-Muñoz JJ, Morón-Verdasco A, Cigarán-Méndez M, et al. Disability, quality of life, personality, cognitive and psychological variables associated with fatigue in patients with multiple sclerosis. Acta Neurol Scand. 2015;132:118–24
- [6] Baschetti R. Chronic fatigue syndrome: an endocrine disease off limits for endocrinologists? Eur J Clin Invest. 2015;33:1029–31
- [7] Jensen MB, Hessov I. Randomization to nutritional intervention at home did not improve postoperative function, fatigue or well-being. Brit J Surg. 2015;84:113–8.
- [8] Arnold ME, Taylor NF. Exercise for patients with cancer: reducing disease-related fatigue. Future Oncol. 2011;7:165–7.
- [9] Mahady GB, Gyllenhaal C, Fong HHS, et al. Ginsengs: a review of safety and efficacy. Nutr Clin Care. 2010;3:90–101.
- [10] Wang Y, Choi H-K, Brinckmann JA, et al. Chemical analysis of Panax quinquefolius (North American ginseng): a review. J Chromatogr A. 2015;1426:1–15.
- [11] In-Ho B, Seung-Ho S. The world ginseng market and the ginseng (Korea). J Ginseng Res. 2013;37:1–7.
- [12] Cho HJ, Choi SH, Kim HJ, et al. Bioactive lipids in gintonin-enriched fraction from ginseng. J Ginseng Res. 2019;43:209–17.
- [13] Saboori S, Falahi E, Rad EY, et al. Effects of ginseng on C-reactive protein level: a systematic review and meta-analysis of clinical trials. Complement Ther Med. 2019;45:98–103.
- [14] Viet BH, Jeongseon K, Seung-Kwon M, et al. Efficacy of ginseng supplements on fatigue and physical performance: a meta-analysis. J Korean Med Sci. 2016;31:1879–86.
- [15] Barton DL, Soori GS, Bauer BA, et al. Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized,

double-blind, dose-finding evaluation: NCCTG trial N03CA. Support Care Cancer. 2010;18:179–87.

- [16] Kim E, Cameron M, Lovera J, et al. American ginseng does not improve fatigue in multiple sclerosis: a single center randomized double-blind placebo-controlled crossover pilot study. Mult Scler. 2011;17:1523–6.
- [17] Barton DL, Liu H, Dakhil SR. Wisconsin ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. J Natl Cancer Inst. 2013;105:1230–8
- [18] Hyeong-Geug K, Jung-Hyo C, Sa-Ra Y, et al. Antifatigue effects of Panax ginseng C.A. Meyer: a randomised, double-blind, placebo-controlled trial. PLoS One. 2013;8:e61271.
- [19] Etemadifar M, Sayahi F, Abtahi SH, et al. Ginseng in the treatment of fatigue in multiple sclerosis: a randomized placebo-controlled double-blind pilot study. Int J Neurosci. 2013;123:480–6.
- [20] Braz AS, Morais LCS, Paula AP, et al. Effects of Panax ginseng extract in patients with fibromyalgia: a 12-week, randomized, double-blind, placebo-controlled trial. Rev Bras Psiquiatr. 2013;35:21–8.
- [21] Hong M, Lee YH, Kim S, et al. Anti-inflammatory and antifatigue effect of Korean red ginseng in patients with nonalcoholic fatty liver disease. J Ginseng Res. 2016;40:203–10
- [22] Hee K, Mi-Kyung K, Maria L, et al. Effect of red ginseng on genotoxicity and health-related quality of life after adjuvant chemotherapy in patients with epithelial ovarian cancer: a randomized, double blind, placebo-controlled trial. Nutrients. 2017;9:772.
- [23] Pourmohamadi K, Ahmadzadeh A, Latifi M. Investigating the effects of oral ginseng on the cancer-related fatigue and quality of life in patients with non-metastatic cancer. Int J Hematol Oncol Stem Cell Res. 2018;12:313.
- [24] Yennurajalingam S, Tannir NM, Williams JL, et al. A double-blind, randomized, placebo-controlled trial of Panax ginseng for cancer-related fatigue in patients with advanced cancer. J Natl Compr Canc Netw. 2017;15:1111–20.
- [25] Sung WS, Kang HR, Jung CY, et al. Efficacy of Korean red ginseng (Panax ginseng) for middle-aged and moderate level of chronic fatigue patients: a randomized, double-blind, placebo-controlled trial. Complement Ther Med. 2019;48:102246.
- [26] Kim JW, Han SW, Cho JY, et al. Korean red ginseng for cancer-related fatigue in colorectal cancer patients with chemotherapy: arandomised phase III trial. Eur J Cancer. 2020;130:51–62.
- [27] Chen W, Yao P, Chi TV, et al. Ginseng: a bibliometric analysis of 40-year journey of global clinical trials. J Adv Res. 2020;34:187–197.
- [28] Kim JH. Cardiovascular diseases and Panax ginseng: a review on molecular mechanisms and medical applications. J Ginseng Res. 2012;36:16–26.
- [29] Arring NM, Millstine D, Marks LA, et al. Ginseng as a treatment for fatigue: a systematic review. J Altern Complement Med. 2018;24:624–33.
- [30] Wang J, Li S, Fan Y, et al. Anti-fatigue activity of the water-soluble polysaccharides isolated from Panax ginseng CA Meyer. J Ethnopharmacol. 2010;130:421–3.
- [31] Morrison J. A power primer: the insignificance of significance in communication research. Florida Commun J. 2010;38:59–76.
- [32] Saltin B, Bangsbo J, Graham TE, et al. Metabolism and performance in exhaustive intense exercise; different effects of muscle glycogen availability, previous exercise and muscle acidity. J Weed Sci Technol. 2015;34:100–1.
- [33] Abdullah A, Javier G, James B. Restoration of muscle glycogen and functional capacity: role of post-exercise carbohydrate and protein co-ingestion. Nutrients. 2018;10:253.
- [34] Yokozawa T, Kobayashi T, Oura H, et al. Stimulation of lipid and sugar metabolism in ginsenoside-Rb. Chem Pharm Bull. 2008;32: 2766–72.
- [35] Bandschapp O, Soule CL, Iaizzo PA. Lactic acid restores skeletal muscle force in an in vitro fatigue model: are voltage-gated chloride channels involved? Am J Physiol Cell Physiol. 2015;302:C1019.
- [36] Kono R, Nomura S, Tokuda A, et al. Effects of citric acid oral intake before low intensity exercise on blood lactic acid and feeling of fatigue—a randomized, double-blind, placebo-controlled, cross-over study. Jpn Pharmacol Ther. 2017;45:395–403.
- [37] Xu X, Dou D. The ginseng's fireness is associated with the lowering activity of liver Na+-K+-F-ATPase. J Ethnopharmacol. 2016;190:241-50.